Cargando…
Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study
BACKGROUND: QVA149 is a once-daily (o.d.) inhaled dual bronchodilator containing a fixed-dose combination of the long-acting β(2)-agonist indacaterol and the long-acting muscarinic antagonist glycopyrronium for the treatment of COPD. The QUANTIFY study compared QVA149 with a free-dose bronchodilator...
Autores principales: | Buhl, Roland, Gessner, Christian, Schuermann, Wolfgang, Foerster, Karin, Sieder, Christian, Hiltl, Simone, Korn, Stephanie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4392202/ https://www.ncbi.nlm.nih.gov/pubmed/25677679 http://dx.doi.org/10.1136/thoraxjnl-2014-206345 |
Ejemplares similares
-
Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study—a randomised controlled trial
por: Frith, Peter A, et al.
Publicado: (2015) -
Efficacy and safety of once-daily single-inhaler triple therapy for mild-to-moderate chronic obstructive pulmonary disease: a study protocol for a randomised and interventional study
por: Takahashi, Koichiro, et al.
Publicado: (2023) -
Measuring respiratory symptoms in clinical trials of COPD: reliability and validity of a daily diary
por: Leidy, N K, et al.
Publicado: (2014) -
Validity and responsiveness of the Daily- and Clinical visit-PROactive Physical Activity in COPD (D-PPAC and C-PPAC) instruments
por: Garcia-Aymerich, Judith, et al.
Publicado: (2021) -
Pharmacodynamics and Pharmacokinetics Following Once-Daily and Twice-Daily Dosing of Tiotropium Respimat(®) in Asthma Using Standardized Sample-Contamination Avoidance
por: Beeh, Kai-Michael, et al.
Publicado: (2016)